Correlation Between Vulcan Materials and CRISPR Therapeutics

Can any of the company-specific risk be diversified away by investing in both Vulcan Materials and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vulcan Materials and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vulcan Materials and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Vulcan Materials and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vulcan Materials with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vulcan Materials and CRISPR Therapeutics.

Diversification Opportunities for Vulcan Materials and CRISPR Therapeutics

-0.53

Correlation Coefficient

Vulcan Materials  CRISPR Therapeutics

Excellent diversification

The 3 months correlation between Vulcan and CRISPR is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Vulcan Materials and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Vulcan Materials is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vulcan Materials are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Vulcan Materials i.e., Vulcan Materials and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between Vulcan Materials and CRISPR Therapeutics

Assuming the 90 days horizon Vulcan Materials is expected to generate 3.99 times less return on investment than CRISPR Therapeutics. But when comparing it to its historical volatility, Vulcan Materials is 2.69 times less risky than CRISPR Therapeutics. It trades about 0.09 of its potential returns per unit of risk. CRISPR Therapeutics AG is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest  4,080  in CRISPR Therapeutics AG on April 20, 2025 and sell it today you would earn a total of  1,470  from holding CRISPR Therapeutics AG or generate 36.03% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Vulcan Materials  vs.  CRISPR Therapeutics AG

Vulcan Materials

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Vulcan Materials are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Vulcan Materials may actually be approaching a critical reversion point that can send shares even higher in August 2025.

CRISPR Therapeutics

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, CRISPR Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Vulcan Materials and CRISPR Therapeutics

The main advantage of trading using opposite Vulcan Materials and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vulcan Materials position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.

The idea behind Vulcan Materials and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.